• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Luna DNA Raises $4M for Community-owned Genomic and Medical Research Database

by Fred Pennic 05/09/2018 Leave a Comment

Luna DNA Raises $4M for Community-owned Genomic and Medical Research Database

Luna DNA, the first community-owned genomic and medical research database has raised $4 million in funding from lead investors Illumina Ventures and Arch Venture Partners. Additional investors include UK-based Bridgelink Capital; Seattle-based Hemisphere Ventures; and Dr. Aristides Patrinos, a former leader of the Human Genome Project and current advisor to Luna DNA. The startup plans to use the funds to support the next phase in creating Luna’s research platform and engaging a global community of data contributors.

Lunda DNA’s community owned genomic and medical research database enables people to share their health data for medical research for the greater good of the community. Members also get to share the earnings that come from medical breakthroughs through shared community ownership of the database. Luna DNA’s approach to medical research and discovery starts with the individual. Founded as a Public Benefit Corporation, Luna believes people have the right to own and share their genomic and health information for the greater good of the community. Through the community-owned approach, members are viewed as equitable partners and awarded shares of ownership in exchange for their DNA and other medical record contributions. Earnings from medical discoveries are passed through to the shareholders. 

“We are proud to have the right partners at our side as we continue on our charter of value creation and the greater good of genomic discovery,” said Dawn Barry, president and co-founder, Luna DNA. “Our team sincerely values our investors’ shared passion for a people-centered model to powering discovery research.”

Tagged With: Clinical Genomics, genomic medicine, genomics data, Luna DNA

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |